Ethics in Clinical Research: 10 Practical Compliance Tips

According to ICH E6, ethical conduct is the first of thirteen core principles of Good Clinical Practice, and every other principle rests on it. Trial design, data integrity, safety monitoring: none of it holds if participants were not informed honestly, treated fairly, or protected when something went wrong.

For coordinators, investigators, and regulatory staff, ethics shows up less as a philosophical question and more as a series of everyday decisions: how a consent conversation goes, how quickly a safety signal gets escalated, how a translated form gets handled. These 10 tips focus on those decisions specifically, drawn from regulatory guidance, audit data, and research on how consent plays out in practice.

Clinical Research Ethics: Key Statistics

Informed consent: top cause of FDA warning letters and inspection findings

41%

Of trial participants had consent reviewed only verbally, with no approved translation (CenterWatch)

Core GCP principles under ICH E6, with ethical conduct listed first

Largest FDA/EMA deficiency categories: documentation and trial management (both include consent failures)

Regulatory framework: ICH E6 and informed consent

✓Informed consent must be documented, ongoing, and reflect the current protocol version

✓IRB-approved forms and approved translations are required; informal workarounds are not compliant

✓Re-consent is required when safety information, procedures, or risk-benefit balance materially changes

✓From a regulatory standpoint, an undocumented action is treated as if it did not happen

In This Article

1. Treat informed consent as a conversation

2. Use only IRB-approved forms and translations

3. Keep consent and protocol in sync

4. Re-consent when material changes occur

5. Build in time for participants under pressure

6. Apply enhanced protections for vulnerable groups

7. Treat new safety information as a consent trigger

8. Get documentation right, completely and at the time

9. Revisit the risk-benefit balance continuously

10. Make ethics training part of onboarding

1. Treat Informed Consent as a Conversation, Not a Signature

A signed form is the record of a conversation, not a substitute for one. Participants need real time to ask questions, think things over, and talk to family before deciding. A University Hospital Galway study using the validated Quality of Informed Consent (QuIC) questionnaire found persistent gaps between what participants thought they had agreed to and what the form actually said.

Effective practice

Walk through key sections of the form together, rather than handing it over and waiting for a signature. Where visit schedules allow, let the participant take the document home before deciding.

Common failure

Handing a participant a 20-page consent form at the start of a long screening visit and asking for a signature at the end. The participant is overwhelmed; the record shows consent obtained.

2. Use Only IRB-Approved Consent Forms and Translations

When a non-English-speaking participant is screened and no approved translation exists, the instinct to have a bilingual staff member walk them through it verbally is the one to resist. CenterWatch’s survey found 41% of participants had consent reviewed verbally only, which helps with comprehension but does not substitute for an IRB-reviewed translated document when language is the actual barrier.

Why informal translations create audit risk

►Creates a mismatch between what the participant heard and what the approved paperwork says

►Auditors are trained to identify exactly this type of inconsistency between verbal and documented consent

►If the translation does not exist, that is a question for the IRB before enrollment, not a workaround for the visit

Common Assessment Finding

In site readiness reviews we conduct ahead of sponsor audits, informal language workarounds are one of the most consistent gaps. Sites document the participant’s primary language in the screening log, enroll them using a form in a language they did not confirm understanding of, and consider the matter resolved. Auditors do not.

3. Keep the Consent Document and Protocol in Sync

A recurring problem flagged in PMC’s review of cancer trial consent practices: the consent form states a procedure happens every visit, while the protocol specifies alternating visits. Nobody intended the discrepancy, but the participant was told something inaccurate regardless.

Protocol amendment sync checklist

✓Cross-check consent form line by line against the schedule of events after every amendment

✓Verify procedure frequency, visit windows, and risk language are consistent between documents

✓Confirm IRB approval of the updated consent form before using it

✓Document version numbers on all forms and retain superseded versions in the regulatory binder

4. Re-Consent Participants Promptly When Anything Material Changes

Consent is not a one-time event, and treating it that way is one of the most frequent and serious findings coordinators encounter during site audits. If new safety information emerges, a protocol is amended, or a procedure changes, the participant’s original signature no longer reflects the study they are actually in.

Re-consent triggers

Trigger

Action required

New safety information

Update consent language; re-consent all active participants

Protocol amendment

Obtain IRB-approved updated form; re-consent affected participants

Procedure change

Update consent document to reflect current procedures before next participant contact

Actionable Takeaway: A version tracker that flags every active participant affected by a consent form update turns re-consent from a manual scramble into a routine check, even across a large enrolled population.

5. Build In Time for Participants Under Pressure

Qualitative interviews with clinical research nurses consistently surface this tension: time constraints and information overload can quietly undermine whether consent is genuinely voluntary, particularly for patients facing serious or advanced illness. A participant who feels they have no real choice, or who is overwhelmed during a single high-stakes visit, has not given truly voluntary consent, even with a signature on file.

Industry Scenario: A patient with a recent serious diagnosis is presented with a trial consent form during the same appointment where they receive their diagnosis. The emotional state of that moment is incompatible with the level of comprehension voluntary consent requires. Where the protocol allows it, scheduling consent at a separate visit is the appropriate standard.

Actionable Takeaway: Offering a follow-up conversation rather than demanding an immediate decision, where the protocol allows it, directly addresses the voluntariness requirement. Document that the option was offered.

Field Observation

In post-audit debrief sessions, we find that coordinators almost universally identify time pressure as the most significant practical barrier to thorough consent conversations. The issue is rarely intent: it is scheduling. Sites that build a dedicated consent appointment into the protocol workflow, separate from screening procedures, consistently perform better on consent-related findings.

6. Apply Enhanced Protections for Vulnerable Groups Before Enrollment Starts

Children, people with limited literacy, economically disadvantaged participants, and other vulnerable groups need protections beyond what a standard adult consent process provides. IRB ethics committees increasingly have to be proactive about how consent methods and digital tools affect these populations, rather than assuming standard procedures are adequate.

Enhanced protections by population

Children: Parental or guardian permission plus age-appropriate assent. Assent language and process must be reviewed by IRB separately from the adult consent form.

Limited literacy: Simplified or plain-language consent documents; oral presentation with witness signature; independent advocate may be required.

Cognitively impaired adults: Capacity assessment before consent; legally authorised representative where required; ongoing capacity monitoring throughout participation.

Caution: The safeguards that matter for vulnerable populations belong in protocol design. Retrofitting them after enrollment has started is harder, less consistent, and will not satisfy an IRB or auditor examining how protections were implemented.

7. Treat New Safety Information as a Trigger to Revisit Consent

When a safety signal appears in another trial of the same product, the first question is whether it needs to be reported. The second, easy to skip, is whether it changes what enrolled participants were told when they signed. If the answer is yes, updated consent language or direct communication with enrolled participants may be required, and that obligation does not expire once enrollment closes.

Two-question check

1. Does this safety information require regulatory reporting?

2. Does it change what participants were told about risk? If yes to either, both questions need answers before the next participant contact.

Common gap

Safety signal is logged and reported. The consent implication is not evaluated. Enrolled participants continue under outdated risk information. This is a consent deficiency, not only a reporting one.

8. Get the Documentation Right, Completely and at the Time

Missing signatures, missing dates, incomplete forms, incorrect consent versions: these appear constantly in audit data. A descriptive analysis of FDA and EMA inspection findings grouped documentation and trial management as the two largest deficiency categories overall, with informed consent issues sitting inside both.

End-of-visit documentation check (one minute)

►Confirm which consent version was used for this visit

►Verify participant signature and date are complete

►Verify investigator or staff countersignature and date are complete

►Confirm a copy has been provided to the participant

Critical: From a regulatory standpoint, an undocumented action is treated as if it did not happen. A well-run consent conversation with a missing signature creates a compliance problem completely out of proportion to how the conversation actually went.

Common Assessment Finding

In regulatory binder reviews, we find outdated consent form versions in active participant files on roughly one in three sites we assess for first-time audits. The version was superseded after a protocol amendment; the coordinator used a form printed before the IRB approved the updated version. The participant and site staff both behaved in good faith. The documentation does not reflect that.

9. Revisit the Risk-Benefit Balance, Not Just at the Start

ICH E6 is explicit that a trial should be initiated, and continued, only if the anticipated benefits justify the risks. What is easy to forget is that this is not a calculation made once during protocol design and filed away.

Key Takeaway: As a trial progresses and new data accumulates, including data from separate studies of the same product, the balance that justified the trial can shift. New efficacy or safety information mid-trial is worth treating as a prompt to actively revisit that justification, not just log and move on.

Industry Scenario: A competing product demonstrates superior efficacy mid-trial. The risk-benefit calculation for continued participation in the existing trial has changed, even if no safety signal has emerged. That change may warrant a protocol review, a consent update, or both.

10. Make Ethics Training Part of Onboarding and Keep It Current

Everyone on a trial, from data managers to investigators, needs both the qualifications and the trial-specific training their role demands under ICH E6, with retraining when protocols change or staff turn over. Training gaps tend to surface as consent-related findings first: the connection between “this person was not retrained after the amendment” and “the wrong consent version is in this participant’s file” usually is not visible until an auditor draws the line between them.

Training documentation requirements

Delegation log: Ties each team member’s assigned responsibilities to their current, documented training. Updated when responsibilities change or training is refreshed.

Protocol-specific training: Required at onboarding and after each protocol amendment. GCP certification alone does not cover trial-specific procedures.

Retraining trigger: Any protocol amendment, significant deviation, or staff role change should prompt a review of whether retraining is required for the affected roles.

Knowledge check

Under ICH E6, how many core GCP principles are there, and where does ethical conduct appear in that list?

Show answer

There are 13 core principles under ICH E6. Ethical conduct is the first principle, and the guideline states that all other principles build on it.

Common Mistakes

Treating consent as a one-time signed event

Build re-consent and ongoing assessment into trial workflows. A participant’s original signature does not cover a study they were not informed about.

Using an informal translation because no approved version exists

A verbal walkthrough by a bilingual staff member does not substitute for an IRB-reviewed translated document. It creates an audit-visible mismatch between what was heard and what the record shows.

Failing to sync the consent form with each protocol amendment

Discrepancies between what the consent form says and what the protocol requires are among the most common consent-related findings across FDA and EMA inspections.

Missing signatures or dates on consent documentation

From a regulatory standpoint, an undocumented action is treated as if it did not happen. A missing date on a consent form is a finding regardless of how well the conversation went.

Applying standard consent procedures to vulnerable populations without modification

Children, participants with limited literacy, and cognitively impaired adults require enhanced protections built into the protocol, not retrofitted after enrollment.

Not re-training staff after protocol amendments

Training gaps surface as consent findings. The delegation log must tie each team member’s responsibilities to current documented training at all times.

Additional Recommendations

Teams looking to go further should review the full set of ICH E6(R2) principles directly rather than relying on summaries, since the guideline’s structure makes clear how interdependent these thirteen principles actually are. A consent version tracking system that automatically flags participants needing re-consent after a form update removes much of the manual burden described above.

For organisations updating their SOPs around informed consent ahead of a sponsor audit or regulatory inspection, a line-by-line review of current consent forms against the approved protocol, IRB correspondence, and delegation logs is the most reliable way to surface gaps before an auditor does.

Ethics in Clinical Research: 10 Practical Tips